Novelty in Biomedicine. 2017; 5 (4): 172-176
in English
| IMEMR
| ID: emr-189668
ABSTRACT
Background:
Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Ribavirin
/
Cross-Sectional Studies
/
Prospective Studies
/
Risk Factors
/
Interferon-alpha
/
Drug Therapy, Combination
Type of study:
Prevalence study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Novelty Biomed.
Year:
2017
Similar
MEDLINE
...
LILACS
LIS